IFNα production by pDCs was increased when activated by a TLR7 agonist, and decreased by the TLR9 pathway, but the expression levels of TLR7 and TLR9 were reported to be comparable in pDCs from SLE patients and healthy controls (65). Here, TLR9 is linked to systemic lupus erythematosus.